THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 118 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2021. The put-call ratio across all filers is 7.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,699,157 | +47.1% | 151,440 | +33.0% | 0.01% | +66.7% |
| Q3 2022 | $1,155,000 | +40.7% | 113,867 | +25.7% | 0.01% | +20.0% |
| Q2 2022 | $821,000 | -44.4% | 90,569 | -41.4% | 0.01% | -58.3% |
| Q1 2022 | $1,477,000 | +59.5% | 154,485 | +84.3% | 0.01% | +33.3% |
| Q4 2021 | $926,000 | +379.8% | 83,822 | +221.4% | 0.01% | +350.0% |
| Q3 2021 | $193,000 | +1.6% | 26,084 | +144.0% | 0.00% | -33.3% |
| Q4 2020 | $190,000 | -70.5% | 10,689 | -65.2% | 0.00% | -72.7% |
| Q2 2020 | $645,000 | -10.4% | 30,751 | +10.6% | 0.01% | -15.4% |
| Q4 2019 | $720,000 | +52.2% | 27,809 | -4.0% | 0.01% | +44.4% |
| Q2 2019 | $473,000 | +56.6% | 28,969 | +117.1% | 0.01% | -10.0% |
| Q1 2019 | $302,000 | +50.2% | 13,342 | +69.8% | 0.01% | +11.1% |
| Q4 2018 | $201,000 | +570.0% | 7,858 | +744.0% | 0.01% | +350.0% |
| Q4 2016 | $30,000 | – | 931 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,012,226 | $78,677,176 | 13.94% |
| Irenic Capital Management LP | 1,700,937 | $19,084,513 | 9.15% |
| Weiss Asset Management LP | 7,457,060 | $83,668,213 | 3.41% |
| Newtyn Management, LLC | 1,450,000 | $16,269,000 | 3.36% |
| Palliser Capital (UK) Ltd | 97,100 | $1,089,462 | 2.65% |
| Chescapmanager LLC | 850,988 | $9,548 | 2.24% |
| Park West Asset Management LLC | 1,920,324 | $21,546,035 | 2.11% |
| Baupost Group | 11,419,226 | $128,124 | 2.09% |
| Saturn V Capital Management LP | 141,339 | $1,334,342 | 1.11% |
| Oasis Management Co Ltd. | 296,960 | $3,331,891 | 0.66% |